Improving Care for Women With Urinary Incontinence (EMPOWER)

Urinary Incontinence Clinical Trial

Official title:

Empowering Women and Providers for Improved Care of Urinary Incontinence (UI) [EMPOWER Study]

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05515198
• Other study ID #: 20211420
• Status: Recruiting
• Phase: N/A
• Start date: September 6, 2022
• Est. completion date: October 31, 2024

Study information

• Verified date: September 2023
• Source: University Hospitals Cleveland Medical Center
• Contact: Ellen Divoky
• Phone: (216) 844-8092
• Email: Ellen.Divoky[@]UHhospitals.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall goal is to improve diagnosis and non-operative management of urinary incontinence in women.

Description:

In the study, patients will be screened in primary care offices for symptoms of urinary incontinence. Women with positive screening results will be asked if they are interested in participating in an implementation study where women will be assigned to one of the three following groups: 1. Usual Care plus Patient Educational Opportunities - The patient's urinary incontinence will be managed using standard of care treatment by the patient's primary care provider. Patients will be offered educational opportunities about urinary incontinence. 2. Nurse Navigation - Along with the treatment described for "Usual Care plus Patient Educational Opportunities," a nurse navigator will work with the patient to implement behavioral changes and provide education and physical therapy options. In addition, the navigator will be available to answer the patient's questions in a timely fashion and help the patient move through the care pathway. 3. Nurse Navigation and ChatBot - Along with the treatment described for "Usual Care plus Patient Educational Opportunities" and "Nurse Navigation," this group will include a ChatBot feature which will allow a patient to directly and privately communicate with an artificial intelligence-driven ChatBot, also known as a "conversational agent," that will provide education and help the patient navigate the care pathway. All participants will complete questionnaires throughout their enrollment and data will be collected from medical records. The study team will analyze the data at six months after the original appointment/study enrollment, assess adherence to therapy and how the therapy impacted the outcomes the team hopes to improve, such as improvement in symptoms. The study will be implemented over three subsequent time periods called Wave 1, Wave 2 and Wave 3 with primary care practices from two geographic regions being involved in each wave (6 regions total). Participants in Wave 1 will be followed for a total of 18 months, while participants in Wave 2 will be followed for a total of 12 months, and participants in Wave 3 will be followed for 6 months. Primary care providers at all participating practices will be offered educational opportunities related to urinary incontinence.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: October 31, 2024
• Est. primary completion date: October 31, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Female patient having a primary care provider visit at University Hospitals (UH) Cleveland Primary Care Institute (PCI)

2. = 18 years old

3. Scores 1 or higher on the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-SF) Exclusion Criteria: None

Related Conditions & MeSH terms

• Enuresis
• Urinary Incontinence

Intervention

Other:
• Patient Education
Patients will be provided educational opportunities.
• Nurse Navigation
A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.
• ChatBot
A ChatBot will allow participants to directly and privately communicate through a smartphone (or other device) with an artificial intelligence-driven ChatBot, also known as a "conversational agent," that will provide education and encouragement to manage their symptoms.

Locations

Country	Name	City	State
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Adonis Hijaz, MD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in patients' UI symptoms as measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF)	The International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) assess frequency, severity and impact on quality of life (QoL) of patients' urinary incontinence symptoms. The result of the ICIQ-UI SF is a composite score ranging from 0 to 21, with higher scores indicating more severe incontinence.	Baseline and Months 2 and 6 (all Waves)
Primary	Patients' UI symptoms as measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF)	The International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) assess frequency, severity and impact on quality of life (QoL) of patients' urinary incontinence symptoms. The result of the ICIQ-UI SF is a composite score ranging from 0 to 21, with higher scores indicating more severe incontinence.	12 months (Waves 1 and 2)
Primary	Patients' UI symptoms as measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF)	The International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) assess frequency, severity and impact on quality of life (QoL) of patients' urinary incontinence symptoms. The result of the ICIQ-UI SF is a composite score ranging from 0 to 21, with higher scores indicating more severe incontinence.	18 months (Wave 1)
Secondary	Change in patients' perceived self-efficacy for UI communication as measured by the PEPPI	Patients' perceived confidence in their ability to communicate their health concerns around UI will be assessed by the Patient-Perceived Self-Efficacy in Patient-Physician Interactions (PEPPI) Questionnaire modified for UI. The PEPPI total score ranges from 0 to 50, with higher scores indicating greater self-efficacy.	Baseline and Months 2 and 6 (all Waves)
Secondary	Patients' perceived self-efficacy for UI communication as measured by the PEPPI	Patients' perceived confidence in their ability to communicate their health concerns around UI will be assessed by the Patient- Perceived Self-Efficacy in Patient-Physician Interactions (PEPPI) Questionnaire modified for UI. The PEPPI total score ranges from 0 to 50, with higher scores indicating greater self-efficacy.	12 months (Waves 1 and 2)
Secondary	Patients' perceived self-efficacy for UI communication as measured by the PEPPI	Patients' perceived confidence in their ability to communicate their health concerns around UI will be assessed by the Patient- Perceived Self-Efficacy in Patient-Physician Interactions (PEPPI) Questionnaire modified for UI. The PEPPI total score ranges from 0 to 50, with higher scores indicating greater self-efficacy.	18 months (Wave 1)
Secondary	Change in patient empowerment as measured by a patient survey	Patient empowerment will be measured by a patient survey to measure with percentage of patients answering yes to speaking with their provider about UI.	Baseline and Months 2 and 6 (all Waves)
Secondary	Change in overactive bladder symptom severity as measured by the OABSS	Patients' overactive bladder symptom severity will be assessed by the Overactive Bladder Symptom Score (OABSS). The OABSS total score ranges from 0 to 15, with higher scores indicating more severe symptoms.	Baseline and Months 2 and 6 (all Waves)
Secondary	Overactive bladder symptom severity as measured by the OABSS	Patients' overactive bladder symptom severity will be assessed by the Overactive Bladder Symptom Score (OABSS). The OABSS total score ranges from 0 to 15, with higher scores indicating more severe symptoms.	12 months (Waves 1 and 2)
Secondary	Overactive bladder symptom severity as measured by the OABSS	Overactive bladder symptom severity will be assessed by the Overactive Bladder Symptom Score (OABSS). The OABSS total score ranges from 0 to 15, with higher scores indicating more severe symptoms.	18 months (Wave 1)
Secondary	Change in urinary symptoms as measured by the UDI-6	How bothersome a patient's urinary symptoms are will be assessed by the Urinary Distress Inventory (UDI-6). The UDI-6 total score ranges from 0 to 100, with higher scores indicating more bothersome symptoms.	Baseline and Months 2 and 6 (all Waves)
Secondary	Urinary symptoms as measured by the UDI-6	How bothersome a patient's urinary symptoms are will be assessed by the Urinary Distress Inventory (UDI-6). The UDI-6 total score ranges from 0 to 100, with higher scores indicating more bothersome symptoms.	12 months (Waves 1 and 2)
Secondary	Urinary symptoms as measured by the UDI-6	How bothersome a patient's urinary symptoms are will be assessed by the Urinary Distress Inventory (UDI-6). The UDI-6 total score ranges from 0 to 100, with higher scores indicating more bothersome symptoms.	18 months (Wave 1)
Secondary	Change in impact of UI on patients' quality of life as measured by the ICIQ-LUTSqol	The impact of urinary incontinence on quality of life will be assessed by the Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol). The ICIQ-LUTSqol total score ranges from 19 to 76, with higher scores indicating increased impact on quality of life.	Baseline and Months 2 and 6 (all Waves)
Secondary	Impact of UI on patients' quality of life as measured by the ICIQ-LUTSqol	The impact of urinary incontinence on quality of life will be assessed by the Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol). The ICIQ-LUTSqol total score ranges from 19 to 76, with higher scores indicating increased impact on quality of life.	12 months (Waves 1 and 2)
Secondary	Impact of UI on patients' quality of life as measured by the ICIQ-LUTSqol	The impact of urinary incontinence on quality of life will be assessed by the Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol). The ICIQ-LUTSqol total score ranges from 19 to 76, with higher scores indicating increased impact on quality of life.	18 months (Wave 1)
Secondary	Change in patients' perceived symptom improvement as measured by the PGI-I	Patients' perceived improvement in UI symptoms will be assessed with the Patient Global Impression of Improvement (PGI-I). PGI-I measures improvement on a scale of 1 "very much better" to 7 "very much worse."	Months 2 and 6 (all Waves)
Secondary	Patients' perceived symptom improvement as measured by the PGI-I	Patients' perceived improvement in UI symptoms will be assessed with the Patient Global Impression of Improvement (PGI-I). PGI-I measures improvement on a scale of 1 "very much better" to 7 "very much worse."	12 months (Waves 1 and 2)
Secondary	Patients' perceived symptom improvement as measured by the PGI-I	Patients' perceived improvement in UI symptoms will be assessed with the Patient Global Impression of Improvement (PGI-I). PGI-I measures improvement on a scale of 1 "very much better" to 7 "very much worse."	18 months (Wave 1)
Secondary	Number of practices that maintain a UI management intervention as measured by the practice survey	Maintenance of UI management intervention will be assessed by practice survey with indication of continuation for each intervention component.	1 month post completion of each Wave's enrollment period
Secondary	Number of practices that implement a UI point person as measured by the practice survey	Implementation of a UI point person will be measured as a percentage of sites answer yes on practice survey.	1 month post completion of each Wave's enrollment period